Metactive Medical, Inc., a Fairway, Kan.-based medical device company developing innovative products for the treatment of neurovascular, peripheral vascular and structural heart diseases, closed an additional $1.2m in Series A financing.
Backers included Mid-America Angels and Serra Ventures.
The round brings the total funding raised by the company to more than $10m to date.
Additionally, Metactive announced that the National Heart, Lung, and Blood Institute of the National Institutes of Health (NIH) was recently awarded a $1.5m Phase 2 SBIR grant to commercialize its over-the-wire Blockstent Microcatheter embolic device for the occlusion of peripheral arteries and veins.
This new investment capital and grant funding will be used to continue the development of its novel platform of embolic products.
Led by F. Nicholas Franano, MD, President and CEO, Metactive is developing innovative new medical devices for the treatment of neurovascular, peripheral vascular, and structural heart diseases. The company’s first products enable precise and immediate occlusion and rapid sealing of arteries, veins, saccular aneurysms, left atrial appendages, and para-valvular leaks using detachable implants and highly flexible catheter delivery systems.